BioNTech
granted for pediatric use low dose vaccination safely high protection | BioNTech
Company
Deck Type
Sector
Industry
Deck date
June 2022
Slide
65 of 156
Related slides by other companies
ATAI
Investor Presentation
January 2023
changes in beta power from dose to hour post dose placebo low dose high dose no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
ATAI
Investor Presentation
March 2023
changes in beta power from dose to hour post dose placebo low doses high doses no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
ATAI
Investor Presentation
February 2023
changes in beta power from dose to hour post dose placebo low dose high dose no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
ATAI
Investor Presentation
April 2023
changes in beta power from dose to hour post dose placebo low doses high doses no significant change significant increase phase data dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action | ATAI
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Results
March 2022
Investor Day
February 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights